Product overview

Product overview

The content of this evidence summary was up to date in August 2021. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.

Delafloxacin (Quofenix, Menarini) is a fluoroquinolone antibiotic, which is available as a powder for infusion and a tablet. It has a marketing authorisation for community-acquired pneumonia in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment. Delafloxacin was launched in the UK in July 2020 for acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. A NICE evidence review on delafloxacin for the treatment of ABSSSI was published in January 2021.